

# Chiara Resnati

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8920418/publications.pdf>

Version: 2024-02-01

20  
papers

171  
citations

1170033

9  
h-index

1255698

13  
g-index

20  
all docs

20  
docs citations

20  
times ranked

362  
citing authors

#	ARTICLE	IF	CITATIONS
1	Toxicovigilance during COVID-19: attention to poisoning related to disinfection. <i>Minerva Anestesiologica</i> , 2021, 87, 251-252.	0.6	2
2	Tenofovir plasma trough concentrations in people with HIV treated with doravirine versus other antiretroviral regimens. <i>Aids</i> , 2021, 35, 2551-2553.	1.0	3
3	Evaluation of the concentrations of psychotropic drugs in HIV-infected versus HIV-negative patients: Potential implications for clinical practice. <i>World Journal of Biological Psychiatry</i> , 2020, 21, 651-657.	1.3	8
4	Binding motif of ebselen in solution: chalcogen and hydrogen bonds team up. <i>New Journal of Chemistry</i> , 2020, 44, 20697-20703.	1.4	20
5	Darunavir Population Pharmacokinetic Model Based on HIV Outpatient Data. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 59-65.	1.0	5
6	The Relevance of Drug-drug Interactions in Clinical Practice: The Case of Concomitant Boosted Protease Inhibitors plus Alpha-1 Blocker Administration. <i>Antiviral Therapy</i> , 2018, 23, 467-469.	0.6	5
7	Dolutegravir and metformin. <i>Aids</i> , 2018, 32, 532-533.	1.0	10
8	Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 86-92.	0.9	25
9	Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals. <i>Aids</i> , 2018, 32, 1995-2004.	1.0	24
10	Correlation between inner retinal layer thickness and cognitive function in HIV. <i>Aids</i> , 2018, 32, 1485-1490.	1.0	11
11	Elvitegravir/Cobicistat-Associated Toxic Optical Neuropathy in an HIV-Infected Patient: A Call for Caution?. <i>Antiviral Therapy</i> , 2017, 22, 453-455.	0.6	4
12	The impact of gastrectomy on the pharmacokinetics of atazanavir and tenofovir. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 789-790.	0.8	3
13	Effect of Legal Status on the Early Treatment Outcomes of Migrants Beginning Combined Antiretroviral Therapy at an Outpatient Clinic in Milan, Italy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 315-321.	0.9	13
14	Pharmacogenetics-based optimisation of atazanavir treatment: potential role of new genetic predictors. <i>Drug Metabolism and Personalized Therapy</i> , 2017, 32, 115-117.	0.3	0
15	Generics for the Treatment of Hepatitis C in Monoinfected And HIV-Coinfected Patients: Pros and Cons. <i>AIDS Reviews</i> , 2017, 19, .	0.5	1
16	Abacavir-induced liver toxicity. <i>Brazilian Journal of Infectious Diseases</i> , 2016, 20, 502-504.	0.3	11
17	Suspected pharmacokinetic interaction between raltegravir and the 3D regimen of ombitasvir, dasabuvir and paritaprevir/ritonavir in an HIV-HCV liver transplant recipient. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 365-367.	0.8	3
18	Comparison of the Pharmacokinetics of Raltegravir Given at 2 Doses of 400 mg by Swallowing Versus One Dose of 800 mg by Chewing in Healthy Volunteers. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 119-125.	1.0	2

#	ARTICLE	IF	CITATIONS
19	Prolonged inductive effect of rifampicin on linezolid exposure. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 643-644.	0.8	10
20	Changes in the Incidence of Severe Thrombocytopenia and Its Predisposing Conditions in HIV-Infected Patients Since the Introduction of Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 67, 493-498.	0.9	11